This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom). Eligible patients are adults who have been treated with isavuconazole in routine practice at participating sites since 15 October, 2015 or since the date of launch in the country if it is after 15 October, 2015 until 30 June, 2019. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants With Clinical Response at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Clinical Response at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Clinical Response at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 6
Timeframe: Week 6 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 12
Timeframe: Week 12 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Radiological Response at Week 24
Timeframe: Week 24 post index date or end of treatment, which ever occurred earlier (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Mycological Response at Week 24
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
All-Cause Mortality at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Adverse Event at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 6
Timeframe: Week 6 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 12
Timeframe: Week 12 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)
Number of Participants With Serious Adverse Event at Week 24
Timeframe: Week 24 post index date (retrospective data extracted and evaluated from study start date and until study completion, approximately 34 months)